Key takeaways
- Build your own catalyst calendar from primary sources: FDA approval and advisory committee calendars, SEC 10-K/10-Q pipeline disclosures, and ClinicalTrials.gov trial records.
- Tradeable biotech catalysts fall into four buckets: PDUFA decisions, clinical readouts, AdCom meetings, and unscheduled events like CRLs or clinical holds.
- Use ClinicalTrials.gov's primary completion date, not the study completion date, to narrow a company's vague quarter guidance into a watchable topline window.
- Log each event with a type, date, and confidence level, then set tiered reminders at T-30, T-7, and T-1 days for high-confidence events.
- Re-verify every calendar date against company filings weekly, because stale dates are worse than no calendar at all.
The fastest way to find biotech stocks with upcoming catalysts is to build your own calendar from primary sources: FDA decision dates on the agency's approval tracker, advisory committee schedules, and ClinicalTrials.gov estimated completion dates. Static ticker lists go stale within days; a calendar you maintain yourself stays current and tells you the exact date, not just the ticker.
What Counts as a Tradeable Biotech Catalyst?
Not every news event moves a ticker. The events that produce the initial move you can trade fall into four buckets, ranked roughly by how hard they hit.
| Catalyst | Typical impact | Predictability |
|---|---|---|
| PDUFA / FDA decision | Binary, gaps the stock | Date known months ahead |
| Clinical readout | Binary, often the biggest mover | Window known, date vague |
| AdCom meeting | High, sets sentiment before PDUFA | Scheduled in advance |
| CRL or clinical hold | Severe, instant repricing | Not scheduled |
PDUFA dates and FDA decision letters
The FDA assigns a goal date under PDUFA. The decision usually lands before or on that date, and the stock gaps on the headline.
Advisory committee (AdCom) meetings
An AdCom's vote often telegraphs the PDUFA outcome weeks early. The FDA posts its advisory committee calendar on fda.gov, so you can see scheduled meetings from the primary source rather than waiting for FinTwit to flag them.
Clinical trial data readouts
Companies guide to a quarter, not a date. You track the window and the trial registry, then trade the release itself.
CRLs, trial holds, and other negative catalysts
Complete response letters and clinical holds arrive unscheduled. If you're short, the edge is being positioned before the print, not reacting after. The same discipline applies to equities generally: see how to start trading stocks.
How Do You Find PDUFA Dates and FDA Decision Dates From the Primary Source?
Secondhand FinTwit lists get you the ticker but not the date, and the date is the trade. Go to the source.
Using the FDA's advisory committee and approvals calendars
The FDA publishes advisory committee meeting schedules and approval actions on fda.gov. AdCom dates are scheduled in advance, so you can mark them months out and watch for schedule changes. Treat the calendar as ground truth, not a Discord screenshot.
Reading company 10-K/10-Q pipeline disclosures
Every listed biotech states its expected regulatory milestones in its 10-K and 10-Q filings on SEC EDGAR. Search the filing for "PDUFA" or the drug's codename and you get the company's own language on timing, plus the risk factors that tell you how the company hedges that date. If a Twitter list and the filing disagree, the filing wins.
Why press-release PDUFA dates can shift
Companies set PDUFA dates as targets, and FDA extensions, complete response letters, and rescheduled reviews move them. A date pulled from a six-month-old press release is stale until you verify it. The discipline is the same one that applies to macro catalysts: confirm the timestamp before you size the trade, the way you would for an FOMC decision (https://trytradar.com/learn/how-to-trade-fomc-meeting).
How Do You Track Clinical Readouts When the Company Only Gives a Quarter?
"H1 2026" is a six-month window, not a date. Your job is to narrow it into something you can actually watch.
ClinicalTrials.gov: primary completion vs study completion
Open the trial record and look at the primary completion date, not the study completion date. Topline data typically lands weeks to a few months after primary completion, once the data is cleaned and locked. If a company says "H1 2026" and the record shows primary completion of March 2026, your realistic topline window is roughly Q2, pushed later if the record gets updated. Check the record's revision history for slipped dates.
Enrollment, data cutoff, and topline timing heuristics
Still-enrolling trials slip; fully enrolled ones with a stated data cutoff are near. A stated "data cutoff" in a press release usually means topline is 6–10 weeks out. For FDA decision timing, the agency publishes goal-date rules under PDUFA performance goals, which is why decision dates are precise while readouts are not.
Setting a watch window, not a watch date
Convert the estimate into a window: expected topline month, plus one buffer month. Alert on anything touching the ticker inside that window, since the XBI moves on sector readouts too (how XBI reacts).
How Do You Build the Calendar Itself?
Step 1: Source Candidates
Pull candidates from three places: XBI constituents for liquid names, screens on Finviz or your broker for market cap and cash runway, and FinTwit watchlists from traders who already cover the space. Aim for 20-40 tickers. More than that and maintenance eats your week; fewer and you miss readouts that move.
Step 2: Log Event Type, Date, and Confidence
For each ticker, record three fields: event type (PDUFA, AdCom, readout window), the date or quarter, and a confidence level. A confirmed FDA decision date gets "high." A company saying "data expected in H2" gets "low" and a range, not a fake precise day. Confidence is what stops you from sizing up on a guess.
This logging step is where most traders quit, because a spreadsheet of dates feels like homework with no payoff until a catalyst actually fires. Push through it. The edge is not knowing a readout is coming; everyone on FinTwit knows that. The edge is knowing, three weeks out, which five names on your list have a binary event, what the consensus expectation is, and whether the date is company-confirmed or community-sourced. That preparation is what lets you trade the initial move instead of chasing it after the first 5 to 10 percent is priced in.
Step 3: Set Tiered Reminders
Set alerts at T-30, T-7, and T-1 days for high-confidence events, and T-7 only for low-confidence ones. If you trade the move itself, pair the calendar with real-time alerts so the calendar tells you when to watch and the alert tells you when to act. The same structure works outside biotech, which is why our tech and semiconductors coverage (https://trytradar.com/news/category/tech-semiconductors) uses the same event-first logic.
Step 4: Weekly Maintenance Pass
Block 30 minutes, same day each week. Check FDA and company press pages for date changes, delete resolved events, and promote or downgrade confidence levels. A calendar you do not maintain is worse than none, because you will trust stale dates.
How Do You Grade Catalysts Before You Trade Them?
Market cap and cash runway context
A PDUFA date on a $300M shell with six months of cash trades differently than the same approval on a $5B company. Check the latest 10-Q for cash on hand and burn rate. Thin runway means dilution risk stacked on top of the binary event, which can flip the direction of the initial move.
Indication size and existing competition
Read the indication on the trial's registration page, not the press release. ClinicalTrials.gov lets you pull enrollment targets, endpoints, and the primary completion date field directly from the record, which is the cleanest way to see how the sponsor structured the study. A small enrollment, an endpoint like progression-free survival instead of overall survival, or a crowded indication with three approved competitors all lower the grade.
Binary risk: position sizing around single events
Grade every entry A, B, or C. A-grade means large indication, clean endpoint, funded company: full planned size. C-grade means any two risk flags stacked: half size or a pass. The same discipline applies to futures catalysts, where you size around the event rather than the headline, as covered in our NVDA technical analysis breakdown.
How Does the Initial Move Actually Trade on an FDA Catalyst?
Pre-market vs after-hours release timing
Most readouts and FDA decisions drop between 7:00 and 9:00 a.m. ET or after the close. A pre-market release gives you regular-session liquidity but a violent open where the first print often gaps past fair value. After-hours releases trade thin, so the initial move can overshoot before the book rebuilds.
The headline-to-fill gap and why speed decides it
The move is priced in within seconds of the headline hitting the wires. Your edge is not reading the press release first; it is having the alert fire and your bracket pre-built before it does. If you are still reading the trial design when NQ-style momentum traders are already in, you are the exit liquidity.
XBI spillover: when one readout moves the sector
A phase 3 miss from a mid-cap can drag the whole biotech complex, and a win can lift peers with similar mechanisms. Watch XBI alongside your single-name position: sector-wide moves are slower and often give a second, cleaner entry than the headline name.
How Do You Keep the Calendar From Going Stale?
Weekly Re-verification Against Primary Sources
Pick one day a week and re-check every date on your calendar against the company's own filings. A 10-K or 10-Q pipeline section often restates expected readout windows and regulatory milestones, and companies quietly revise them between quarters. If a company slides a Phase 3 topline from Q3 to "second half," the calendar entry moves or gets flagged. SEC filings are searchable free through EDGAR, the SEC's filing database.
Alerting on Company Press Releases and FDA Announcements
Set alerts on each ticker's press releases and on FDA approval action announcements, so a date change or early readout reaches you in minutes, not days. This is the same principle behind Tradar's real-time alerts for traders: the catalyst moves the tape the moment it hits the primary source, and by the time FinTwit is posting about it, part of the move is priced in.
Where Manual Calendars Break and Automation Helps
Manual calendars fail at exactly one step: nobody re-checks 40 tickers weekly forever. Dates drift, trials get suspended, and the spreadsheet silently rots. Automated pipelines that pull filings and press releases into your alert stack cover the gap, though they cost setup time and can still miss a Friday-evening FDA press release, so keep a manual sweep for high-conviction positions.
Which Tools Do Catalyst Traders Actually Use?
Free primary sources vs paid alert platforms
ClinicalTrials.gov, FDA advisory calendars, and company IR pages cost nothing and are the primary sources your edge depends on. The tradeoff is latency and assembly: you pull the PDUFA date, the readout window, and the AdCom schedule yourself. Paid alert platforms like CNBC: Stock Market & Business, Bloomberg: Business News Daily, Yahoo Finance: Stocks, Markets, Seeking Alpha: News & Analysis, and Stocks News: Market Headlines compress that work, but most push headlines after the move has started.
Running Tradar through the same criteria — and where it falls short
Tradar (Market News Alerts) grades the same way this calendar does: real-time alerts, impact score, trust score, sub-minute delivery so you trade the catalyst, not the noise. Where it falls short: it is a general market news alert app, not a biotech calendar builder. It will not assemble your PDUFA and readout list for you. You still build the calendar from primary sources; Tradar covers the delivery layer.
When a manual spreadsheet beats any app
Early on, a spreadsheet wins. Building it teaches you which catalysts you actually trade, and nothing gets stale faster than a feed you did not configure. Move to an app once volume justifies it.
FAQ
How far in advance should I start watching a PDUFA date?
Start watching at least 30 days out, since that is when the first tier of reminders fires on high-confidence events. The FDA goal date is known months ahead, so log it early, verify it against the company's latest 10-Q rather than an old press release, and downgrade confidence immediately if an extension or rescheduled review shifts it.
Where can I find a free list of upcoming FDA advisory committee meetings?
The FDA publishes its advisory committee meeting schedules directly on fda.gov, which costs nothing and serves as the primary source. AdCom dates are scheduled in advance, so you can mark them months out and monitor for changes. Treat that calendar as ground truth rather than screenshots or watchlists circulating on FinTwit, which often carry stale or secondhand dates.
How do you track clinical readouts when the company only gives a quarter?
Open the trial record on ClinicalTrials.gov and use the primary completion date, not the study completion date. Topline data typically lands weeks to a few months after primary completion, once the data is cleaned and locked. If a company says H1 2026 and the record shows March 2026, your realistic topline window is roughly Q2, and the record's revision history reveals slipped dates.